uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Levodopa Fractionation in Parkinson's Disease
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
2014 (English)In: Journal of Parkinson's Disease, ISSN 1877-718X, Vol. 4, no 1, 89-96 p.Article in journal (Refereed) Published
Abstract [en]

Background:

Fractionation of daily levodopa dosage is one strategy to manage the almost inevitable development of symptom fluctuations in Parkinson's disease (PD). However, it is not known from the literature how levodopa fractionation is performed in routine clinical practice.

Objective:

The objective of this study was to capture how anti-parkinsonian medications were used, in particular how the daily dose was fractionated (defined as >4 doses/day).

Methods:

A pharmacoepidemiological study was undertaken at Uppsala University Hospital. Medical records of PD patients with ≥4 years' disease duration who visited the Neurology Clinic between January and October 2011 were retrospectively reviewed. Times to dose fractionation, to dyskinesias and to hallucinations were calculated using Kaplan-Meier analyses.

Results:

175 patients (47% women) were included. Median age at PD onset was 63 years (range 36-83). Median disease duration was 9.0 years. Dose fractionation was used in 85% of patients. The median time to fractionation was 5.0 years. Patients developing dyskinesias had a significantly earlier age at onset than those who did not.

Conclusions:

Fractionation of levodopa dosage into >4 daily doses was common. It occurred when wearing-off of the levodopa response is expected to present, i.e. after 5 years in 50% of patients. The study highlights the importance of individualizing and frequently adjusting levodopa dosage, already from the initiation of therapy.

Place, publisher, year, edition, pages
2014. Vol. 4, no 1, 89-96 p.
National Category
Neurology
Identifiers
URN: urn:nbn:se:uu:diva-216791DOI: 10.3233/JPD-130244ISI: 000331810500010PubMedID: 24398654OAI: oai:DiVA.org:uu-216791DiVA: diva2:690808
Available from: 2014-01-24 Created: 2014-01-24 Last updated: 2014-04-04Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Nyholm, Dag

Search in DiVA

By author/editor
Nyholm, Dag
By organisation
Neurology
Neurology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 698 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf